Zymeworks Inc. presented new preclinical data for its antibody-drug conjugate (ADC) candidates ZW220 and ZW251 at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference on October 25, 2024. The data highlighted the potential of these innovatively designed molecules, which incorporate Zymeworks' proprietary payload, ZD06519.
ZW220, a NaPi2b-directed topoisomerase I inhibitor ADC, demonstrated compelling preclinical activity in models of non-small cell lung, ovarian, and uterine cancers, along with a favorable toxicology profile in non-human primates. This data supports an Investigational New Drug (IND) submission in the first half of 2025, suggesting potential improvements over previous NaPi2b ADCs.
Similarly, ZW251, a novel glypican-3-targeting ADC, showed compelling preclinical activity in hepatocellular carcinoma models, supporting an IND submission in the second half of 2025. ZW251 demonstrated strong anti-tumor activity across various models and significant tolerability in non-human primate studies at doses up to 120 mg/kg, indicating its promise as a new treatment option.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.